Product Program year 2025 Source: CMS Open Payments

Eylea

Biological Ophthalmology

NDC 61755-005-02

Open in the dashboard

General payments

$12,269,879

36,710 payments

Research payments

$53,649,315

4,935 payments

Through program year 2025, $12,269,879 in general payments and $53,649,315 in research payments were reported against Eylea (Ophthalmology).

No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.

By program year

14 rows
Year Kind Amount Payments
2025 General $241,595 1,697
2025 Research $3,366,935 285
2024 General $553,143 3,148
2024 Research $1,924,211 139
2023 General $1,780,239 6,765
2023 Research $2,159,357 129
2022 General $2,520,502 8,585
2022 Research $13,663,691 1,241
2021 General $2,265,496 5,894
2021 Research $18,816,313 1,432
2020 General $2,190,799 3,746
2020 Research $5,931,516 520
2019 General $2,718,105 6,875
2019 Research $7,787,292 1,189

Breakdown

Who paid General payments · program years 2019–2025
  1. Regeneron Healthcare Solutions, Inc. $10,411,316 34,041 payments
  2. Regeneron Pharmaceuticals, Inc. $1,858,563 2,669 payments
Top recipients General payments · program year 2025
  1. Shaheen Kavoussi Ophthalmology · Houston, TX $14,426 6% · 13 payments
  2. Seenu Hariprasad Ophthalmology · Chicago, IL $13,720 6% · 17 payments
  3. Michael Javaheri Retina Specialist · Beverly Hills, CA $13,291 6% · 6 payments
  4. Ehsan Rahimy Retina Specialist · Stanford, CA $8,541 4% · 6 payments
  5. Jonathan Jonisch Ophthalmology · Great Neck, NY $7,199 3% · 4 payments

The top 5 of the 100 largest recipients; each share is of general payments naming this product in 2025.

The top 25 recipients, free in the app

Specialties paid General payments · program year 2025
  1. Ophthalmology $121,109 58% · 435 practitioners
  2. Retina Specialist Ophthalmology $71,995 35% · 228 practitioners
  3. Optometrist $11,810 6% · 69 practitioners
  4. Uveitis and Ocular Inflammatory Disease Ophthalmology $1,641 <1% · 4 practitioners
  5. Internal Medicine $321 <1% · 4 practitioners

The top 5 of 17 specialties; each share is of general payments naming this product to practitioners with a specialty in 2025. Each practitioner is counted under their primary specialty.

The top 25 specialties, free in the app

Where the money went General payments · program year 2025
  1. California $68,619 28% · 106 recipients
  2. Florida $25,690 11% · 128 recipients
  3. Texas $24,266 10% · 55 recipients
  4. Illinois $19,606 8% · 18 recipients
  5. New York $14,146 6% · 27 recipients

The top 5 of 37 states; each share is of general payments naming this product in 2025 where a state was reported.

The top 25 states, free in the app

Prescribed to Medicare patients

Part D · data year 2024

Part D claims

31,095

Prescriptions dispensed, refills included

Drug cost

$78,055,252

Paid at the pharmacy, in all

Medicare Part D drugs matched to EYLEA, 2024
Part D drug Name match Relative to the largest Prescribers Claims Drug cost
Eylea Aflibercept Same name 247 28,056 $68,106,055
Eylea Hd Aflibercept Similar name 59 3,039 $9,949,197

Matched to this product by name; CMS does not link its files to Open Payments, so a similar name can be a different strength, form or brand. Prescriber counts include only prescribers with 11 or more claims of the drug, because CMS publishes nothing below that. Part D covers drugs dispensed to Medicare beneficiaries at a pharmacy; it does not include drugs given in a clinic or hospital, or patients with other insurance.

Largest prescribers

First 5 of 109 by claims · 2024

Two separate records. Claims come from Medicare and related payments from Open Payments. They are shown in one row because they name the same product; they do not show that a payment affected a prescription.

The prescribers with the most Part D claims of this drug in 2024
Prescriber Specialty State Claims Drug cost Related payments
Wilfredo Lara Ophthalmology FL 1,288 $2,974,194 $34
Larry Perich Ophthalmology FL 1,109 $2,719,225 None on record
Sulaiman Alhumaid Ophthalmology FL 874 $1,864,960 $55
Charles Brodrick Ophthalmology TX 847 $2,600,256 None on record
Kenneth Wals Ophthalmology FL 826 $1,838,322 None on record

"No profile" means the prescriber has no Open Payments record here; "None on record" means no payment naming this product in the payment year. Related payments are general payments, and one that names several products is split evenly, so an amount is payments related to the product, not money paid for it. The list is the prescribers with the most claims, up to 100 per drug.

See more in the dashboard: 25 with a free account, all 109 with Patron

Given in the clinic

Part B · billing code
Medicare Part B billing codes matched to EYLEA
Billing code Providers Services Paid by Medicare
Injection, aflibercept, 1 mg J0178 3,155 2,690,616 $1,756,326,816

Drugs given by a clinician are billed to Medicare Part B, not Part D. The product is tied to a billing code through the NDC on CMS's crosswalk, which was published for a later quarter than the payments, so a code that changed in between can be missed. Providers with fewer than 11 patients for the code are not published. Medicare's payment here is what it paid for the services, to the billing practice.

36,710 general · 4,935 research

Every payment, record by record

Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.

What you are looking at

Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record